LYSADERM
Financiado
Platelet LYSAte based DERMal formulation for the treatment of skin ulcers
The LYSADERM project aims at the fabrication of a medicinal cream containing Platelet Lysate (PL), that can be used for the topical therapy of skin ulcers. The applicant company Episkey is an innovative start-up founded in 2016 wi...
The LYSADERM project aims at the fabrication of a medicinal cream containing Platelet Lysate (PL), that can be used for the topical therapy of skin ulcers. The applicant company Episkey is an innovative start-up founded in 2016 with the aim of introducing into the market novel therapeutic products obtained from human Platelet Lysate. Episkey holds the exclusive licenses of international patents covering the therapeutic administration of cord blood Platelet Lysate, and already developed an international network of cord blood banks aimed at the procurement of Cord Blood Platelet Lysate for pharmaceutical transformation into platelet derivatives and drugs. Within the broad scope of our company mission, the LYSADERM project aims at marketing a novel formulation of dermatological cream containing tissue regenerative factors present in human platelets. The LYSADERM dermatological cream will be therefore used for the treatment of skin ulcers, including serious disorders, such as diabetic foot ulcers, pressure ulcers and leg ulcers. LYSADERM aims to be the first pharmaceutical cream containing Platelet Lysate, and it is expected to improve healing of the ulcers in comparison to conventional treatments, at lower cost; therefore, it would become the standard procedure to treat diabetic foot ulcers, pressure ulcers and leg ulcers. The LYSADERM business project is expected to generate positive outcomes for the whole society, such as the increase of effectiveness in the treatment of skin ulcers both in hospitals and at the patient’s home. It is roughly estimated that once industrialized, LYSADERM can generate in just 5 years a total of over 10 M annual revenues, covering the 0.4% of the EU market share. Overall, the main objective of our phase I project is to achieve the technical definition of the LYSADERM product, to realize a complete exploitation plan, and to consolidate our business plan through a second-level FTO and the definition of the financial forecasts.
ver más
Duración del proyecto: 4 meses
Fecha Inicio: 2018-05-09
Fecha Fin: 2018-09-30
Fecha Fin: 2018-09-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
EPISKEY SRL
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
951.65K€ |
Participante